Patents by Inventor Herve PUY

Herve PUY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
    Patent number: 9873877
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 23, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Laurent Gouya, Jean-Charles Deybach, Herve Puy, Vincent Oustric
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA
    Publication number: 20170247705
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.
    Type: Application
    Filed: March 24, 2017
    Publication date: August 31, 2017
    Inventors: Laurent GOUYA, Jean-Charles DEYBACH, Herve PUY, Vincent OUSTRIC
  • Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
    Patent number: 9637744
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: May 2, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Laurent Gouya, Jean-Charles Deybach, Herve Puy, Vincent Oustric
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA
    Publication number: 20160122767
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 5, 2016
    Inventors: Laurent GOUYA, Jean-Charles DEYBACH, Herve PUY, Vincent OUSTRIC